Results 201 to 210 of about 42,124 (246)
Some of the next articles are maybe not open access.
Mechanisms of tamoxifen resistance
Breast Cancer Research and Treatment, 1994Though the antiestrogen tamoxifen prolongs disease-free and overall survival in the adjuvant setting, and induces remissions in over half of the patients with estrogen receptor positive metastatic disease, all patients eventually acquire tamoxifen resistance.
C K, Osborne, S A, Fuqua
openaire +2 more sources
Tamoxifen resistance in breast cancer
Critical Reviews in Oncology/Hematology, 1993Tamoxifen (TAM) resistance is the underlying cause of treatment failure in many breast cancer patients receiving TAM. The mechanism(s) involved in TAM resistance are poorly understood. A variety of mechanisms have been proposed but only limited evidence exists to substantiate them.
V J, Wiebe +3 more
openaire +2 more sources
Reduced tamoxifen accumulation is not associated with stimulated growth in tamoxifen resistance
Cancer Chemotherapy and Pharmacology, 1994To study tamoxifen resistance-stimulated growth, 30 female ovariectomized nude mice were implanted with tamoxifen-resistant tumors and treated with 10-1000 micrograms/day of tamoxifen citrate subcutaneously. Tamoxifen stimulated MCF-7 tumor growth in a dose-dependent manner, with tumoral tamoxifen concentrations increasing proportionally to the dose (1-
J, Maenpaa +6 more
openaire +2 more sources
A Review on The Role of VEGF in Tamoxifen Resistance
Anti-Cancer Agents in Medicinal Chemistry, 2019Background: Certain molecular deviations can lead to the development of breast cancer. For instance, estrogen and estrogen receptors play a significant role in inducing tumor proliferation. However, the efficacy of endocrine therapy through the administration of anti-estrogen drugs, such as Tamoxifen, is challenged by acquired resistance. Methods:
Sepideh, Mansouri +4 more
openaire +2 more sources
Tamoxifen resistance: From bench to bedside
European Journal of Pharmacology, 2013Although tamoxifen is a classical example of a targeted drug, a substantial proportion of estrogen receptor alpha positive breast cancer patients does not benefit from the drug. Over the last few decades, many potential biomarkers have been discovered in cell biological studies that may aid in the prediction of tamoxifen sensitivity and guide in ...
Marjolein, Droog +3 more
openaire +2 more sources
Tamoxifen Therapy in Steroid-Resistant Riedels Disease
Scottish Medical Journal, 2002Riedel s thyroiditis is a rare chronic inflammatory disorder characterised by extensive fibrosis of the thyroid gland and sometimes the surrounding tissues. We report a case of Riedel s Thyroiditis in a middle aged female presenting with goitre, stridor and dyspnoea. She initially responded to corticosteroid treatment and subsequently to tamoxifen. The
M, De, A, Jaap, J, Dempster
openaire +2 more sources
Mechanisms for tamoxifen resistance in breast cancer: Possible role of tamoxifen metabolism
The Journal of Steroid Biochemistry and Molecular Biology, 1993Potential mechanisms for tamoxifen resistance include loss or alteration in estrogen receptor or other transcription factors and altered tamoxifen pharmacology. Using an experimental model, we have previously demonstrated that one form of tamoxifen resistance is related to the acquired ability of tamoxifen to stimulate tumor growth.
openaire +2 more sources
The effect of renin angiotensin system on tamoxifen resistance
Medical Hypotheses, 2011Breast cancer is one of the most common forms of cancer observed in women and endogenous estrogens are thought to play a major role in its development. Tamoxifen is a selective estrogen receptor (ER) modulator which is widely used to treat and prevent breast cancer. Tamoxifen is an ER antagonist in the breast but an ER agonist in cardiovascular system (
Soha, Namazi +2 more
openaire +2 more sources
An in vitro model for the development of acquired tamoxifen resistance
Cell Biology and Toxicology, 2016The development of resistance to tamoxifen (Tam) remains a challenging clinical problem for ER+ breast cancer patients. To understand the mechanisms underlying of resistance, previous studies have driven the acquisition of Tam resistance by exposing cells to varying concentration of drug for varying lengths of time. However, a detailed protocol for the
Güney Eskiler, Gamze +3 more
openaire +3 more sources
Tamoxifen induces resistance to activated protein C
Thrombosis Research, 2014The estrogen antagonist tamoxifen (TAM) increases the thrombotic risk similar to estrogen containing oral contraceptives (OC). In OC users this risk is attributed to alterations of hemostasis resulting in acquired resistance to activated protein C (APC).
Heiko, Rühl +9 more
openaire +2 more sources